Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis

Total Page:16

File Type:pdf, Size:1020Kb

Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis Published OnlineFirst December 15, 2015; DOI: 10.1158/0008-5472.CAN-14-3595 Cancer Molecular and Cellular Pathobiology Research Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis Cheng Xing1, Xing-Xing Lu2, Peng-Da Guo2, Tong Shen2, Shen Zhang2, Xiao-Shun He2, Wen-Juan Gan2, Xiu-Ming Li2, Jing-Ru Wang2, Yuan-Yuan Zhao2, Hua Wu2, and Jian-Ming Li1,2 Abstract Ubiquitin specific protease 4 (USP4) is a deubiquitinating Mechanistically, we observed that USP4 interacted with and enzyme with key roles in the regulation of p53 and TGFb stabilized PRL-3 via deubiquitination. This resulted in activa- signaling, suggesting its importance in tumorigenesis. Howev- tion of Akt and reduction of E-cadherin, critical regulators of er, the mechanisms and regulatory roles of USP4 in cancer, cancer cell growth and metastasis. Examination of clinical including colorectal cancer, remain largely elusive. Here, we samples confirmed that USP4 expression positively correlates present the first evidence that USP4 regulates the growth, with PRL-3 protein expression, but not mRNA transcript levels. invasion, and metastasis of colorectal cancer. USP4 expression Taken together, our results demonstrate that aberrant expres- was significantly elevated in colorectal cancer tissues and was sion of USP4 contributes to the development and progression significantly associated with tumor size, differentiation, distant of colorectal cancer and reveal a critical mechanism underlying metastasis, and poor survival. Knockdown of USP4 diminished USP4-mediated oncogenic activity. These observations suggest colorectal cancer cell growth, colony formation, migration, and that the potential of harnessing proteolytic degradation pro- invasion in vitro and metastasis in vivo. Importantly, we found cesses for therapeutic manipulationmayofferamuch-needed that phosphatase of regenerating liver-3 (PRL-3) is indispens- new approach for improving colorectal cancer treatment able for USP4-mediated oncogenic activity in colorectal cancer. strategies. Cancer Res; 76(1); 1–13. Ó2015 AACR. Introduction cell-cycle progression, transcriptional regulation, and signal trans- duction (3–5). However, deubiquitination, the reverse process Colorectal cancer is the third leading cause of death from cancer mediated by deubiquitinating enzymes (DUB), has gained worldwide (1). Although some advances have been made in the increasing attention as an important regulatory mechanism in treatment of colorectal cancer, including surgical techniques, che- controlling protein turnover (6, 7). Currently, approximately 100 motherapy, and radiation therapy, the overall survival rate of putative DUBs have been identified (8), but most have not been patients with colorectal cancer has not improved dramatically. This functionally characterized. The ubiquitin-specific proteases (USP) is due to recurrence and metastasis (2). Altered regulation of some represent the largest subclass of DUBs. It has more than 50 proteins and signaling pathways in the development of colorectal members (8). Like other USPs, USP4 also mediates the removal cancer has been described, but identification of novel regulatory and processing of ubiquitin. USP4 binds TRAF2, TRAF6, and mechanisms contributing to the development and progression of TAK1 for deubiquitination and negatively regulates TNFa- colorectal cancer remains a subject of significant interest. induced NF-kB activation (9, 10). USP4 binds directly to and Ubiquitination is an essential posttranslational modification. It stabilizes ARF-BP1 via deubiquitination, subsequently promoting plays critical roles in a diverse array of cellular processes, including ARF-BP1–dependent p53 ubiquitination and degradation (11). USP4 also directly interacts with and deubiquitinates TGFb type I receptor (TbRI), regulating TGFb signaling by controlling TbRI 1Department of Pathology, Nanfang Hospital, Southern Medical Uni- versity, Guangzhou, China. 2Pathology Center and Department of levels at the plasma membrane (12). USP4 is significantly over- Pathology, Soochow University, Suzhou, China. expressed in many human cancers, such as urinary, prostate, Note: Supplementary data for this article are available at Cancer Research thyroid, and liver cancer (11, 13). Unfortunately, other studies Online (http://cancerres.aacrjournals.org/). show conflicting observations. USP4 protein expression is down- Corresponding Authors: Jian-Ming Li, Department of Pathology, Nanfang regulated in lung cancer cell lines (14). USP4, which is located on Hospital, Southern Medical University, Guangzhou 510515, China. Phone: 86- chromosome 3 (3p21.3), is frequently deleted in human epithe- 512-65882673; Fax: 86-512-65882673; E-mail: lixinyue@fimmu.com; and Hua lial cancers, including those of the breast, kidney, and lung Wu, Pathology Center and Department of Pathology, Soochow University, (15–17). However, USP4's mechanism of regulation in cancer, Suzhou 215123, China. Phone: 86-512-65882673; Fax: 86-512-65882673; E-mail: including colorectal cancer, has not been well established. [email protected] Phosphatase of regenerating liver-3 (PRL-3, also called doi: 10.1158/0008-5472.CAN-14-3595 PTP4A3), a member of the protein tyrosine phosphatase family Ó2015 American Association for Cancer Research. (PTPs), plays an important role in cancer progression, including www.aacrjournals.org OF1 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2015 American Association for Cancer Research. Published OnlineFirst December 15, 2015; DOI: 10.1158/0008-5472.CAN-14-3595 Xing et al. cell proliferation, migration, invasion, metastasis, and angiogen- tissues were purchased from Shanghai Outdo Biotech Co., Ltd., esis (18–20). The expression of PRL-3 is frequently upregulated in collected between 2006 and 2007. A total of 167 patients were human tumors, such as breast cancer (21), liver cancer (22), involved in the study. The clinical characteristics of all patients are ovarian cancer (23), gastric cancer (24), and colorectal cancer listed in Supplementary Table S1. The study was approved by (25). This expression is associated with cancer progression and Soochow University for Biomedical Research Ethics Committee, poor survival. PRL-3 modulates multiple signaling pathways, and all of the patients provided informed consent. Tissues were including PI3K/AKT, SRC, Rho GTPases, MAPK/ERK, and EGFR probed using the indicated antibodies. in various cancer cells (19, 26, 27). Previous findings, including The staining score was evaluated using two blinded individuals. ours, clearly indicate that PRL-3 plays a critical role in the epi- The staining scoring criteria were as follows: 0, 1%–4% of the cells thelial–mesenchymal transition (EMT; refs. 28, 29). Recently, a stained positive; 1, 5%–25% of the cells stained positive; 2, 26%– new functional role of PRL-3 in epigenetic regulation was dis- 50% of the cells stained positive; 3, 51%–75% of the cells stained covered. PRL-3 probably affects the activity of JMJD1B and positive; and 4, 75% of the cells stained positive. The staining JMJD2B, two histone demethylases, thus participating in the intensity of cancer cells was scored as 0 (no staining), 1 (weak regulation of histone methylation (30). Despite PRL-3's impor- staining), 2 (intermediate staining), and 3 (strong staining). An tance as a regulatory of tumorigenesis, the mechanism leading to intensity score of 2 with at least 50% of USP4-positive cells was the aberrant upregulation of PRL-3 in tumors remains unclear. regarded as high expression, and <50% of USP4-positive cells or In this study, results showed USP4 expression to be elevated in <2 in intensity score was considered low expression. The multiple tumor tissues sampled from colorectal cancer patients. A series of of the intensity and extent score was used as the final score (0–12) experiments in vitro and in vivo revealed that stable knockdown of for USP4. USP4 expression in colorectal cancer cells significantly impaired the capacity for growth, migration, invasion, and metastasis. In Generation of stable cell lines addition, the mechanism by which USP4 promotes development HCT116 and SW480 cell lines stably expressing USP4-specific and progression of colorectal cancer was investigated. USP4 shRNA (USP4/shRNA) or scrambled shRNA control (USP4/Ctr) activates PI3K/AKT signaling and downregulates E-cadherin were constructed using a lentiviral shRNA technique. Oligonu- expression by binding to and deubiquitinating PRL-3, thereby cleotides were constructed in GV248 lentiviral RNAi vector preventing degradation of PRL-3. Collectively, these results sug- (GeneChem). SW480 and HCT116 cells were transduced with gest that USP4 is a bona fide DUB of PRL-3 and plays a pivotal role serial dilutions of lentiviral supernatant and selected for using in colorectal cancer. 5 mg/mL puromycin for 3 to 4 weeks. The human USP4 shRNA target sequences are listed in Supplementary Table S2. Materials and Methods siRNA Antibody and reagents Human USP4 and PRL-3 siRNA and siRNA nonspecific control Antibodies against USP4 (#2651), p-Akt (#9271), and Akt were synthesized by RiboBio. Colorectal cancer cells were tran- (#9272) were purchased from Cell Signaling Technology. siently transfected with these siRNAs using Lipofectamine 2000. E-cadherin (ab53033) and PRL-3 (ab50276) were purchased The human USP4 and PRL-3 siRNA target sequences are listed in from Abcam. HA (F-7) and C-myc (9E10) were purchased from Supplementary Table S3. Santa
Recommended publications
  • Binding of Sap102 and Usp4 to the A2a
    Diplomarbeit BINDING OF SAP102 AND USP4 TO THE A2A ADENOSINE RECEPTOR CARBOXYTERMINUS Zur Erlangung des akademischen Grades Doktorin der Zahnheilkunde (Dr. med. dent.) an der Medizinischen Universität Wien ausgeführt am Institut für Pharmakologie unter der Anleitung von Prof. Dr. Christian Nanoff eingereicht von Ivana Ostrouska Matr.Nr.: n0347690 Gallmeyergasse 6/1/5, A-1190 Wien Wien, 31.März 2009 Diploma Thesis BINDING OF SAP102 AND USP4 TO THE A2A ADENOSINE RECEPTOR CARBOXYTERMINUS Obtainment of the academic degree Doctor of Dentistry (Dr. med. dent.) at the Medical University Vienna performed at the Institute of Pharmacology supervised by Prof. Dr. Christian Nanoff submitted by Ivana Ostrouska Matr.No.: n0347690 Gallmeyergasse 6/1/5, A-1190 Vienna Vienna, 31.March 2009 My very best thanks to Christian Nanoff, Oliver Kudlacek, Ingrid Gsandtner and to the Institute of Pharmacology. 3 Content 1 Summary ................................................................................................................ 11 2 Introduction ........................................................................................................... 12 2.1 The A2A adenosine receptor..................................................................................... 12 2.1.1 A2A receptor signaling.......................................................................................... 15 2.2 Synapse Associated Proteins and SAP102 .............................................................. 17 2.2.1 SAP Structure.....................................................................................................
    [Show full text]
  • The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid
    The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome Annette K. Brenner, Elise Aasebø, Maria Hernandez-Valladares, Frode Selheim, Frode Berven, Ida-Sofie Grønningsæter, Sushma Bartaula-Brevik and Øystein Bruserud Supplementary Material S2 of S31 Table S1. Detailed information about the 68 AML patients included in the study. # of blasts Viability Proliferation Cytokine Viable cells Change in ID Gender Age Etiology FAB Cytogenetics Mutations CD34 Colonies (109/L) (%) 48 h (cpm) secretion (106) 5 weeks phenotype 1 M 42 de novo 241 M2 normal Flt3 pos 31.0 3848 low 0.24 7 yes 2 M 82 MF 12.4 M2 t(9;22) wt pos 81.6 74,686 low 1.43 969 yes 3 F 49 CML/relapse 149 M2 complex n.d. pos 26.2 3472 low 0.08 n.d. no 4 M 33 de novo 62.0 M2 normal wt pos 67.5 6206 low 0.08 6.5 no 5 M 71 relapse 91.0 M4 normal NPM1 pos 63.5 21,331 low 0.17 n.d. yes 6 M 83 de novo 109 M1 n.d. wt pos 19.1 8764 low 1.65 693 no 7 F 77 MDS 26.4 M1 normal wt pos 89.4 53,799 high 3.43 2746 no 8 M 46 de novo 26.9 M1 normal NPM1 n.d. n.d. 3472 low 1.56 n.d. no 9 M 68 MF 50.8 M4 normal D835 pos 69.4 1640 low 0.08 n.d.
    [Show full text]
  • A Study on the E3 Ligase TRIM21/Ro52 Alexander Espinosa from the Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Thesis for doctoral degree (Ph.D.) 2008 Thesis for doctoral degree (Ph.D.) 2008 A STUDY ON THE E3 LIGASE TRIM21/RO52 A study on the E3 ligase TRIM21/Ro52 ligase E3 the on study A Alexander Espinosa Alexander Espinosa Fredrik Bredin From the Department of Medicine, Karolinska Institutet, Stockholm, Sweden A STUDY ON THE E3 LIGASE TRIM21/Ro52 Alexander Espinosa All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Larserics Digital Print AB, Box 20082, SE-161 02 Bromma, Sweden. © Alexander Espinosa, 2008 ISBN 978-91-7357-480-8 iii ABSTRACT Patients with the systemic autoimmune diseases Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE), often have antibodies against the intracellular protein TRIM21/Ro52. Although the presence of anti-TRIM21/Ro52 autoantibodies is used as a diagnostic tool, the biological function of TRIM21/Ro52 is still unknown. The aim of this thesis is to provide a better understanding of the function of TRIM21/Ro52, especially regarding its role in autoimmunity. To achieve this, TRIM21/Ro52 was studied at a molecular and cellular level in vitro and in vivo. By using circular dichroism, limited proteolysis, mass spectrometry, ultra-centrifugation, and two- hybrid experiments, it was shown that TRIM21/Ro52 is a Zn2+ binding protein that forms weak dimers. These results also confirmed the presence of the predicted secondary structure domains of TRIM21/Ro52. A RING domain in the N-terminus of TRIM21/Ro52 suggests that TRIM21/Ro52 is a RING dependent E3 ligase. Through ubiquitination assays, it was shown that TRIM/Ro52 is indeed an E3 ligase and that the E3 ligase activity of TRIM21/Ro52 was dependent on the E2 enzymes UbcH5a-c or UbcH6.
    [Show full text]
  • Cell Proliferation Control: from Intrinsic Transcriptional Programs to Extrinsic Stromal Networks
    Cell Proliferation Control: from Intrinsic Transcriptional Programs to Extrinsic Stromal Networks DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Huayang Liu Graduate Program in Molecular Genetics The Ohio State University 2015 Dissertation Committee: Professor Gustavo Leone, Advisor Professor Helen Chamberlin Professor Harold Fisk Professor Tsonwin Hai Copyright by Huayang Liu 2015 Abstract Robust mechanisms to control cell proliferation have evolved to maintain the integrity of organ architecture and tissue homeostasis. Disruption of these mechanisms, either intracellular circuits or extracellular inputs for cell proliferation control, inevitably occur under oncogenic conditions, rendering cells with unlimited proliferative capacity and subsequent malignant transformation. Here, we investigated how two critical intracellular proliferative pathways, Myc and E2f, are integrated to control cell cycle transitions in normal and Rb deficient cells using a murine intestinal model. We show that in contrast to the current paradigm, Myc and E2f1-3 have little impact on normal G1- S transitions. Instead Myc and E2f1-3 synergistically control an S-G2 transcriptional program in intestinal crypts required for completing normal cell divisions and maintaining crypt-villi integrity. Surprisingly, Rb deficiency results in the Myc- dependent accumulation of E2f3a protein and the genome-wide repositioning of Myc and E2f3 on chromatin associated with ‘super activation’ of a G1-S transcriptional program, ectopic S phase entry and rampant cell proliferation. These findings reveal that Rb deficient cells hijack and redeploy Myc and E2f3 from an S-G2 program essential for normal cell cycles to a G1-S program that re-engages ectopic cell cycles, exposing an unanticipated addiction of Rb-null ‘cancer-like cells’ on Myc.
    [Show full text]
  • Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis
    Published OnlineFirst December 15, 2015; DOI: 10.1158/0008-5472.CAN-14-3595 Cancer Molecular and Cellular Pathobiology Research Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis Cheng Xing1, Xing-Xing Lu2, Peng-Da Guo2, Tong Shen2, Shen Zhang2, Xiao-Shun He2, Wen-Juan Gan2, Xiu-Ming Li2, Jing-Ru Wang2, Yuan-Yuan Zhao2, Hua Wu2, and Jian-Ming Li1,2 Abstract Ubiquitin specific protease 4 (USP4) is a deubiquitinating Mechanistically, we observed that USP4 interacted with and enzyme with key roles in the regulation of p53 and TGFb stabilized PRL-3 via deubiquitination. This resulted in activa- signaling, suggesting its importance in tumorigenesis. Howev- tion of Akt and reduction of E-cadherin, critical regulators of er, the mechanisms and regulatory roles of USP4 in cancer, cancer cell growth and metastasis. Examination of clinical including colorectal cancer, remain largely elusive. Here, we samples confirmed that USP4 expression positively correlates present the first evidence that USP4 regulates the growth, with PRL-3 protein expression, but not mRNA transcript levels. invasion, and metastasis of colorectal cancer. USP4 expression Taken together, our results demonstrate that aberrant expres- was significantly elevated in colorectal cancer tissues and was sion of USP4 contributes to the development and progression significantly associated with tumor size, differentiation, distant of colorectal cancer and reveal a critical mechanism underlying metastasis, and poor survival. Knockdown of USP4 diminished USP4-mediated oncogenic activity. These observations suggest colorectal cancer cell growth, colony formation, migration, and that the potential of harnessing proteolytic degradation pro- invasion in vitro and metastasis in vivo.
    [Show full text]
  • Deciphering the Functional Redundancy of USP4 and USP15 by Sarah Zachariah a Thesis Submitted in Partial Fulfillment of the Requ
    Deciphering the functional redundancy of USP4 and USP15 by Sarah Zachariah A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in Biochemistry Department of Biochemistry, Microbiology, Immunology Faculty of Medicine University of Ottawa Supervisor: Dr. Douglas Gray © Sarah Zachariah, Ottawa, Canada, 2020 i ABSTRACT The deubiquitinating enzymes USP4 and USP15 are encoded by genes that are ohnologues arising from whole genome duplication events early in vertebrate evolution, and the majority of known vertebrate genomes contain a functional copy of both. Both USPs are known to be involved in some of the same signalling pathways such as Wnt/β-catenin, however subfunctionalization has occurred such that they each regulate the stability of distinct substrates. Despite their sequence and evolutionary similarities, the ohnologues may have opposite correlations in overall survival of lung adenocarcinoma patients. Early work with knockout mice has determined that while mice null in one ohnologue display no phenotype, the double null genotype is lethal. We hypothesize that there are mechanisms in place that allow one to perform the other’s functions to a certain extent when deficient in one USP. To study the extent of this functional redundancy, we are analyzing the progeny of genetic crosses of mice in which one or both genes have been inactivated. There is evidence for partial functional redundancy and more severe phenotypes when deficient in USP15. Embryos null for both genes die at midgestation and are physically smaller than embryos heterozygous for both genes. They have underdeveloped livers, and a likely defect in hematopoiesis. Proper fetal hematopoiesis requires signalling through Wnt/ β-catenin pathway, and a systematic analysis of the components of this pathway has been undertaken to correlate deficiencies with the genotypes of our knockout mice.
    [Show full text]
  • Role of Deubiquitinases in Human Cancers: Potential Targeted Therapy
    International Journal of Molecular Sciences Review Role of Deubiquitinases in Human Cancers: Potential Targeted Therapy Keng Po Lai 1 , Jian Chen 1,* and William Ka Fai Tse 2,* 1 Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541004, China; [email protected] 2 Center for Promotion of International Education and Research, Faculty of Agriculture, Kyushu University, Fukuoka 819-0395, Japan * Correspondence: [email protected] (J.C.); [email protected] (W.K.F.T.); Tel.: +86-773-5895810 (J.C.); +81-92-802-4767 (W.K.F.T.) Received: 25 February 2020; Accepted: 1 April 2020; Published: 6 April 2020 Abstract: Deubiquitinases (DUBs) are involved in various cellular functions. They deconjugate ubiquitin (UBQ) from ubiquitylated substrates to regulate their activity and stability. Studies on the roles of deubiquitylation have been conducted in various cancers to identify the carcinogenic roles of DUBs. In this review, we evaluate the biological roles of DUBs in cancer, including proliferation, cell cycle control, apoptosis, the DNA damage response, tumor suppression, oncogenesis, and metastasis. This review mainly focuses on the regulation of different downstream effectors and pathways via biochemical regulation and posttranslational modifications. We summarize the relationship between DUBs and human cancers and discuss the potential of DUBs as therapeutic targets for cancer treatment. This review also provides basic knowledge of DUBs in the development of cancers and highlights the importance of DUBs in cancer biology. Keywords: deubiquitinase; degradation; therapeutic target; cancer 1. Introduction Deubiquitinases (DUBs) deconjugate ubiquitin (UBQ) from ubiquitylated substrates to regulate their activities and stability.
    [Show full text]
  • USP4 Antibody A
    Revision 1 C 0 2 - t USP4 Antibody a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 1 5 Web: [email protected] 6 www.cellsignal.com 2 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source: UniProt ID: Entrez-Gene Id: WB H M R Mk Endogenous 104, 109 Rabbit Q13107 7375 Product Usage Information 1. Nijman, S.M. et al. (2005) Cell 123, 773-86. 2. Nalepa, G. et al. (2006) Nat Rev Drug Discov 5, 596-613. Application Dilution 3. Gupta, K. et al. (1994) Oncogene 9, 1729-31. 4. Gupta, K. et al. (1993) Oncogene 8, 2307-10. Western Blotting 1:1000 5. Papa, F.R. and Hochstrasser, M. (1993) Nature 366, 313-9. 6. Gray, D.A. et al. (1995) Oncogene 10, 2179-83. Storage 7. Gilchrist, C.A. et al. (1997) J Biol Chem 272, 32280-5. 8. Gilchrist, C.A. and Baker, R.T. (2000) Biochim Biophys Acta 1481, 297-309. Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% 9. Zhang, X. et al. (2011) EMBO J 30, 2177-89. glycerol. Store at –20°C. Do not aliquot the antibody. 10. Blanchette, P. et al. (2001) Oncogene 20, 5533-7. 11. DeSalle, L.M. et al. (2001) Oncogene 20, 5538-42. Specificity / Sensitivity USP4 Antibody recognizes endogenous levels of total USP4 protein. Based upon sequence alignment, this antibody is predicted to cross-react with the UnpEL and UnpES isoforms of USP4.
    [Show full text]
  • Inhibition of USP4 Attenuates Pathological Scarring by Downregulation of the TGF‑Β/Smad Signaling Pathway
    MOLECULAR MEDICINE REPORTS 20: 1429-1435, 2019 Inhibition of USP4 attenuates pathological scarring by downregulation of the TGF‑β/Smad signaling pathway JIE ZHANG, SIJIA NA, SHUTING PAN, SANG LONG, YUQI XIN, QINGKUN JIANG, ZHONGWEI LAI, JUNFENG YAN and ZHONGYI CAO Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China Received October 16, 2018; Accepted April 17, 2019 DOI: 10.3892/mmr.2019.10370 Abstract. Pathological scarring is a result of the hypertrophy Introduction of scar tissue during tissue repair following trauma. The aim of the present study was to assess the effect of ubiquitin‑specific Scars are the products of wound healing by the human protease 4 (USP4) silencing on pathological scarring, and to body. Among them, hypertrophic scars (HS) and keloids evaluate the mechanistic basis for the effect. An MTT assay are known as pathological scars, which are characterized by was used to assess cell viability. Immunoprecipitation (IP) was sustained hyperactive growth, irregular scar shape, and an used to determine ubiquitination levels of the TGF-β receptor uneven and tough texture (1). Pathological scars are the result (TβR)I and Smad7. Tumor formation was assessed by injecting of hypertrophy of scar tissue in the process of tissue repair keloid fibroblasts. Hematoxylin and eosin staining was used to following trauma. Pathological scars have serious aesthetic detect pathological changes in tumor tissue. Reverse transcrip- effects and result in tissue dysfunction due to deformities tion quantitative polymerase chain reaction and western blot of the scar contractures, particularly at the joints. Certain analysis assays were used to evaluate the expression levels of patients experience pain, itching, ulceration and the develop- TβRI and Smad7.
    [Show full text]
  • USP4 Antibody (Internal) Rabbit Polyclonal Antibody Catalog # ALS10995
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 USP4 Antibody (Internal) Rabbit Polyclonal Antibody Catalog # ALS10995 Specification USP4 Antibody (Internal) - Product Information Application IHC Primary Accession Q13107 Reactivity Human, Rabbit, Monkey, Pig, Bovine, Dog Host Rabbit Clonality Polyclonal Calculated MW 109kDa KDa USP4 Antibody (Internal) - Additional Information Gene ID 7375 Anti-USP4 antibody ALS10995 IHC of human Other Names thymus. Ubiquitin carboxyl-terminal hydrolase 4, 3.4.19.12, Deubiquitinating enzyme 4, Ubiquitin thioesterase 4, USP4 Antibody (Internal) - Background Ubiquitin-specific-processing protease 4, Ubiquitous nuclear protein homolog, USP4, Hydrolase that deubiquitinates target UNP, UNPH proteins such as the receptor ADORA2A, PDPK1 and TRIM21. Deubiquitination of ADORA2A Target/Specificity increases the amount of functional receptor at Human USP4. BLAST analysis of the peptide the cell surface. May regulate mRNA splicing immunogen showed no homology with through deubiquitination of the U4 other human proteins. spliceosomal protein PRPF3. This may prevent its recognition by the U5 component PRPF8 Reconstitution & Storage thereby destabilizing interactions within the Long term: -70°C; Short term: +4°C U4/U6.U5 snRNP. May also play a role in the regulation of quality control in the ER. Precautions USP4 Antibody (Internal) is for research use USP4 Antibody (Internal) - References only and not for use in diagnostic or therapeutic procedures. Gray D.A.,et al.Oncogene 10:2179-2183(1995). Gray D.A.,et al.Submitted (OCT-1997) to the USP4 Antibody (Internal) - Protein Information EMBL/GenBank/DDBJ databases. Frederick A.,et al.Oncogene 16:153-165(1998). Name USP4 Ota T.,et al.Nat.
    [Show full text]
  • The Deubiquitinase USP4 Stabilizes Twist1 Protein to Promote Lung Cancer Cell Stemness
    cancers Article The Deubiquitinase USP4 Stabilizes Twist1 Protein to Promote Lung Cancer Cell Stemness Fengtian Li y, Qingyong Hu y, Tao He, Jing Xu, Yong Yi , Siyi Xie, Liangping Ding, Mengyuan Fu, Rongtian Guo, Zhi-Xiong Jim Xiao * and Mengmeng Niu * Center of Growth, Metabolism and Aging, Key Laboratory of Bio-Resource and Eco-Environment, Ministry of Education, College of Life Sciences, Sichuan University, Chengdu 610065, China; [email protected] (F.L.); [email protected] (Q.H.); [email protected] (T.H.); [email protected] (J.X.); [email protected] (Y.Y.); [email protected] (S.X.); [email protected] (L.D.); [email protected] (M.F.); [email protected] (R.G.) * Correspondence: [email protected] (Z.-X.J.X.); [email protected] (M.N.); Tel./Fax: +86-28-8541-0034 (Z.-X.J.X.) These authors contributed equally to this work. y Received: 28 April 2020; Accepted: 7 June 2020; Published: 15 June 2020 Abstract: Lung cancer stem cells (CSCs) play a pivotal role in tumor development, drug resistance, metastasis and recurrence of lung cancer. Thus, it is of great importance to study the mechanism by which CSCs are regulated. In this study, we demonstrate that the deubiquitinase USP4 is critically important in promoting lung cancer stemness. Silencing of USP4 leads to reduction of Oct4 and Sox2 expression, decreased CD133+ cell population and inhibition of tumorsphere formation. Conversely, ectopic expression of USP4 significantly enhances lung cancer cell stemness, which is effectively rescued by simultaneous silencing of Twist1. Mechanistically, we identified USP4 as a novel deubiquitinase of Twist1.
    [Show full text]
  • USP4 Promotes Invasion of Breast Cancer Cells Via Relaxin/TGF-Β1/Smad2/MMP-9 Signal
    European Review for Medical and Pharmacological Sciences 2016; 20: 1115-1122 USP4 promotes invasion of breast cancer cells via Relaxin/TGF-β1/Smad2/MMP-9 signal W.-H. CAO1, X.-P. LIU2, S.-L. MENG3, Y.-W. GAO3, Y. WANG1, Z.-L. MA1, X.-G. WANG1, H.-B. WANG1 1Department of Breast Surgery, the Affiliated Hospital of Qingdao University, Qingdao, China 2Department of Central Laboratory, the Affiliated Hospital of Qingdao University, Qingdao, China 3Department of Gynaecology, People’s Hospital of Zhangqiu, Jinan, China Abstract. – OBJECTIVE: Ubiquitin-specific = dimethyl sulfoxide; BB94, batimastat; PBS, phosphate protease 4 (USP4) is a deubiquitinating enzyme buffered saline; FBS, fetal bovine serum; DMEM, Dul- with key roles in the regulation of TGF-β1 signal- becco’s modified Eagle medium; IMDM, Iscove’s modi- ing, suggesting its importance in tumorigenesis. fied Dulbecco’s medium. However, the underlying mechanisms causing this are not entirely clear. In the present study, we investigated the effect of USP4 on invasion Introduction and tumorigenesis of breast cancer cells, and explored its mechanism. MATERIALS AND METHODS: Breast cancer is the second-fourth leading cause Effects of USP4 of cancer-related deaths in women in the world, overexpression or USP4 silencing by small inter- fering RNA (USP4 siRNA) on invasion of breast suggesting that early diagnosis and prevention of 1 cancer MDA-MB-231 and T47D cells in vitro was this disease is urgently needed . Currently, breast detected. Using siRNAs and inhibitors to exam- cancer is treated with surgery, chemotherapy, and ine the USP4 signaling pathway. radiation therapy or combined modalities with RESULTS: The migration and invasion assays remarkable success.
    [Show full text]